A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2013 |
| Start Date: | November 2001 |
| End Date: | November 2013 |
| Contact: | Quynh-Thu Le |
| Email: | qle@stanford.edu |
| Phone: | (650) 498-6184 |
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA
concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients
with nasopharyngeal carcinoma (NPC).
2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these
tumors both in endemic and non-endemic areas.
3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for
both endemic and non-endemic patient populations.
Inclusion Criteria:
- Having a new diagnosis of Nasopharyngeal carcinoma.
- Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion Criteria:
- Age <18 since NPC is a very rare condition in this age group and may have a different
biological behavior
- Patients who are unable to provide informed consents for themselves.
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
